查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2139057

基礎編輯市場：依編輯器類型、功能、環境、適應症及最終用戶分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Base Editing Market By Editor Type, Delivery, Setting, Indication, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球鹼基編輯市場正經歷快速成長，這主要得益於對精準基因組編輯技術投資的不斷增加、基因治療的進步以及針對疾病相關基因突變療法的研究不斷深入。預計到2025年，該市場規模約為3.01億美元，到2035年將達到約70.388億美元。這一顯著的市場擴張主要源自於鹼基編輯技術從新興研究領域轉向臨床前研究和臨床開發領域的轉變。

這反映出一種趨勢，即加速向應用範圍不斷擴大的平台轉型，涵蓋從生物技術到治療藥物商業化的各個領域。

預計2026年至2035年預測期內，該領域的複合年成長率（CAGR）約為37.1%。這一成長預示著未來十年該領域將迎來強勁擴張，這得益於腺嘌呤和胞嘧啶鹼基編輯器的持續研發、引導RNA設計的改進、遞送技術的進步以及基因編輯在遺傳疾病和慢性疾病領域應用的不斷拓展。研究人員和生物技術公司正致力於推進鹼基編輯研究，以實現靶向核苷酸轉化，同時避免像許多傳統的基於核酸酶的編輯方法那樣造成DNA雙鏈鏈斷裂。

顯著的市場趨勢

請詳細重寫每個段落，無需小標題。 「目前主導鹼基編輯市場的五大領導公司。」Beam Therapeutics：純鹼基編輯領域的先驅。其專有技術能夠實現精確的單鹼基DNA修飾，且不會造成雙鏈。丹納赫公司：透過其子公司Integrated DNA Technologies (IDT)主導市場供應鏈。丹納赫提供全球鹼基編輯研發所需的寡核苷酸、工具和試劑。 Prime Medicine：鹼基編輯技術（一種先進的延伸技術）的領導者。其高度特異性的「搜尋和替換」技術可以糾正大多數已知的基因突變。

Verve Therapeutics：體內鹼基編輯應用領域的領先先驅。 Verve 利用創新的脂質奈米顆粒遞送技術，透過精準編輯靶向心血管疾病的基因，樹立了新的臨床標準。 Intellia Therapeutics：基因組編輯巨頭，正迅速擴展其鹼基編輯能力。其在全身性體內 CRISPR 遞送方面無與倫比的專業知識以及不斷取得的臨床里程碑，鞏固了其顯著的市場佔有率。

這些公司凸顯了不斷發展的精準基因組編輯市場中競爭和准入的多元化特徵。 Beam Therapeutics專注於治療性鹼基編輯，而禮來公司收購Verve則為大型製藥企業帶來了先進的心血管鹼基編輯平台。 Prime Medicine正透過Prime Edit拓展在非切割編輯領域的業務，而丹納赫的IDT則提供重要的核酸研究基礎設施。

同時，儘管Interior公司目前的主要臨床項目並非採用傳統的鹼基編輯方法，但它已展現出先進的CRISPR遞送技術和臨床開發能力的重要性。這種經營模式和技術策略的多樣性有助於基因組編輯生態系統的更廣泛發展，並擴大精準基因療法的潛在應用範圍。

關鍵成長要素

2026年，推動人們對鹼基編輯療法興趣日益濃厚的主要因素之一是美國基因組編輯和基因療法產品監管框架的不斷改進。美國食品藥物管理局（FDA）已推出多項舉措，旨在透過幫助研發人員利用現有的科學、生產、非臨床和臨床知識，提高細胞療法和基因療法的研發效率。 2026年6月，FDA發布了在基因組編輯技術應用於人類基因治療產品研發過程中如何利用現有知識的指導草案。該指導草案概述了申辦方如何利用現有的公開資訊和平台知識，包括相關的化學、生產和品管（CMC）、非臨床和臨床信息，以減少重複的研發活動。此外，FDA也推出了關於基因組編輯安全性評估、個人化醫療和CMC柔軟性的指導和舉措，展現了其在維持適當的安全性和品質標準的同時，促進更有效率研發的更廣泛的監管策略。

新機會的趨勢

在生物製藥領域，由於業界對基因修飾技術的準確性、安全性和可預測性日益成長的需求，向非切割式、高精度基因組編輯的轉變正成為重要的市場成長機會。傳統的基因組編輯方法依賴雙鏈DNA斷裂，這可能導致後續DNA修復過程中出現非預期的基因突變，引發脫靶效應、插入缺失、染色體重排以及基因組整體穩定性等方面的挑戰。隨著生物製藥開發商越來越重視開發需要高度可控基因修飾的療法，市場對能夠在實現標靶修飾的同時最大限度減少對DNA分子不必要損傷的編輯技術的需求也日益成長。

最佳化障礙

技術限制和潛在的脫靶效應構成重大挑戰，可能阻礙全球鹼基編輯市場的成長。儘管鹼基編輯技術旨在實現標靶核苷酸替換，避免人為造成DNA雙鏈斷裂，但該技術仍依賴引導RNA、編輯酶和標靶DNA序列之間極為精確的分子間相互作用。基因組背景、標靶可及性、編輯酶活性以及細胞環境的變異性都會影響編輯效率和特異性。這些限制因素使得在不同的基因標靶和患者群體中難以達到一致的治療效果。

目錄

第1章執行摘要

  • 全球基礎編輯市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 主要訊息
    • 次要訊息
  • 量化研究
    • 主要訊息
    • 次要訊息
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球鹼基編輯市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球基礎編輯產業概覽
    • 過渡到更安全的單核苷酸編輯（雙鏈）和一次性體內根治性治療（PCSK9/ANGPTL3）
    • ABE（約佔致病突變的 50%）、透過 LNP 進行肝臟遞送、基於平台的 FDA 策略、體外同種異體 CAR-T 多重化以及脫靶安全性基礎設施的優勢。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 按編輯類型進行的價格趨勢分析

第4章：全球資料庫編輯市場分析

  • 競爭對手儀錶板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球資料庫編輯市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 按編輯類型
      • 關鍵見解
        • 檸檬貝斯 編輯
        • 腺嘌呤鹼基編輯器
        • 基於RNA的編輯器
    • 報價
      • 關鍵見解
        • 脂質奈米顆粒
        • AAV/病毒載體
        • 離體電穿孔
    • 透過環境
      • 關鍵見解
        • In Vivo
        • Ex Vivo
    • 適應症
      • 關鍵見解
        • 心血管/血脂異常症
        • 血紅素疾病
        • 肝臟與代謝
        • 免疫學和腫瘤學
        • 罕見遺傳疾病
    • 最終用戶
      • 關鍵見解
        • 生物製藥
        • 學術與研究
        • CDMO
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

公司簡介（公司概況、財務指標、主要產品清單、主要負責人、主要競爭對手、聯絡資訊和業務策略展望）

  • Beam Therapeutics
  • Verve Therapeutics (Eli Lilly)
  • Prime Medicine
  • Korro Bio
  • Wave Life Sciences
  • ProQR Therapeutics
  • Chroma Medicine (nChroma Bio)
  • Base Therapeutics
  • YolTech Therapeutics
  • Broad Institute (licensor)
  • Pfizer
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Editas Medicine
  • BEAM-Apellis collaborations
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA09261966

The global base editing market is experiencing rapid expansion, driven by increasing investment in precision genome-editing technologies, advances in genetic medicine, and growing research into therapies capable of addressing disease-associated genetic mutations. The market is estimated to be valued at approximately USD 300.1 million in 2025 and is projected to reach around USD 7,038.8 million by 2035. This substantial increase in market value reflects the accelerating transition of base editing from an emerging research technology toward a platform with expanding applications in preclinical research, clinical development,

biotechnology, and potential therapeutic commercialization.

The projected growth corresponds to a compound annual growth rate (CAGR) of approximately 37.1% during the 2026-2035 forecast period. Such a growth rate indicates strong expected expansion over the decade, supported by continued development of adenine and cytosine base editors, improvements in guide-RNA design, advances in delivery technologies, and increasing efforts to apply gene editing to inherited and chronic diseases. Researchers and biotechnology companies are increasingly exploring base editing because it can enable targeted nucleotide conversions without intentionally generating the double-strand DNA breaks associated with many conventional nuclease-based editing approaches.

Noteworthy Market Developments

Rewrite in detail in paragraphs without subheadings Top 5 Players Currently Dominating the Base Editing Market. Beam Therapeutics: The undisputed pioneer in pure base editing. Their proprietary technology enables precise, single-base DNA modifications without double-strand breaks. Danaher Corporation: Dominates the market's supply chain via its subsidiary, Integrated DNA Technologies (IDT). Danaher provides the critical oligonucleotides, tools, and reagents essential for global base editing R&D. Prime Medicine: Leads in "prime editing," an advanced extension of base editing. Its highly specific "search-and-replace" technology can correct a vast majority of known genetic mutations.

Verve Therapeutics: A major frontrunner in in vivo base editing applications. Verve leverages innovative lipid nanoparticle delivery to precisely edit genes targeting cardiovascular diseases, setting new clinical benchmarks. Intellia Therapeutics: A genome-editing giant rapidly expanding its base editing capabilities. Its unmatched expertise in systemic in vivo CRISPR delivery and continuous clinical milestones reinforce its significant market share.

These companies illustrate the different layers of competition and participation within the evolving precision genome-editing market. Beam Therapeutics has a direct focus on therapeutic base editing, while Eli Lilly's acquisition of Verve has brought an advanced cardiovascular base-editing platform into a large pharmaceutical organization. Prime Medicine is expanding the non-cleaving editing landscape through prime editing, while Danaher's IDT contributes essential nucleic-acid research infrastructure.

Intellia, meanwhile, demonstrates the importance of advanced CRISPR delivery and clinical development capabilities, even though its principal clinical programs currently rely on approaches other than conventional base editing. This diversity of business models and technological strategies is contributing to the broader development of the genome-editing ecosystem and expanding the potential applications of precision genetic medicines.

Core Growth Drivers

A major factor supporting the growing interest in base editing therapeutics in 2026 is the evolution of regulatory frameworks governing genome-editing and gene therapy products in the United States. The U.S. Food and Drug Administration (FDA) has introduced several initiatives aimed at making the development of cell and gene therapies more efficient by allowing developers to leverage established scientific, manufacturing, nonclinical, and clinical knowledge. In June 2026, the FDA issued draft guidance on leveraging prior knowledge in the development of human gene therapy products incorporating genome editing. The guidance outlines how sponsors may potentially use existing public and platform knowledge, including relevant chemistry, manufacturing and controls (CMC), nonclinical, and clinical information, to reduce redundant development activities. The FDA has also introduced guidance and initiatives addressing genome-editing safety assessments, individualized therapies, and CMC flexibility, indicating a broader regulatory effort to facilitate more efficient development while maintaining appropriate safety and quality standards.

Emerging Opportunity Trends

The shift toward non-cleaving precision genome editing is emerging as a significant opportunity for market growth within the biopharmaceutical sector, driven by the industry's growing emphasis on improving the precision, safety, and predictability of genetic modification technologies. Conventional genome-editing approaches that depend on creating double-strand DNA breaks can introduce unintended genetic alterations during the subsequent DNA repair process, creating challenges related to off-target activity, insertions and deletions, chromosomal rearrangements, and overall genomic stability. As biopharmaceutical developers increasingly focus on the development of therapies that require highly controlled genetic modifications, there is growing demand for editing technologies capable of achieving targeted changes while minimizing unnecessary damage to the DNA molecule.

Barriers to Optimization

Technical limitations and the potential for off-target effects represent significant challenges that may restrain the growth of the global base editing market. Although base editing was developed to enable targeted nucleotide changes without intentionally generating double-strand DNA breaks, the technology remains dependent on highly precise molecular interactions between the guide RNA, editing enzyme, and target DNA sequence. Variations in genomic context, target accessibility, editor activity, and cellular environment can affect editing efficiency and specificity. These limitations can make it difficult to achieve consistent therapeutic performance across different genetic targets and patient populations.

Detailed Market Segmentation

By editor type, adenine base editors (ABEs) represent a major segment of the base editing market in 2026, supported by their ability to mediate precise A*T-to-G*C base-pair conversions. ABEs are designed to chemically modify adenine within DNA, ultimately enabling the targeted conversion of an adenine-thymine base pair into a guanine-cytosine base pair without requiring the DNA molecule to undergo a conventional double-strand break. This capability has made ABEs an important platform for investigating genetic disorders in which pathogenic variants can potentially be corrected through this type of nucleotide conversion.

By delivery method, lipid nanoparticles (LNPs) represented a leading delivery platform in the base editing market in 2025 and continued to hold an important position. LNPs are particularly attractive because they can encapsulate and transport nucleic-acid-based therapeutic components, including messenger RNA and guide RNA, into target cells. Their ability to facilitate intracellular delivery without requiring permanent genetic expression has made them an important technology for advancing transient gene-editing approaches, particularly those intended to modify genetic sequences directly within the patient's body.

By Setting, the ex vivo setting holds a major share within the base editing market as of 2025. In order to support this growth, patient-derived cells can be processed and manipulated in laboratory conditions before they are returned to the patient. An ex vivo approach involves collecting cells from an individual and transferring them to a lab or manufacturing facility where base editing machinery is introduced to modify genetic sequences. Before being administered back to the patient, the edited cells are expanded, tested, and subjected to quality-control procedures. In applications involving cell-based therapies, ex vivo approaches are particularly appealing because they provide researchers and developers with greater opportunities to characterize the edited cells before treatment.

By indication, cardiovascular and lipid disorders represent a major therapeutic focus within the global base editing market, accounting for nearly 28% of the market according to the stated market estimates. The strong concentration of base editing research and development in this therapeutic area is largely associated with the substantial global burden of cardiovascular disease and the well-established relationship between specific genetic targets and lipid metabolism. The availability of extensively studied molecular targets provides researchers with a relatively well-defined pathway for evaluating the potential of base editing as a therapeutic approach, particularly for conditions associated with elevated low-density lipoprotein cholesterol (LDL-C) and other cardiovascular risk factors.

Segment Breakdown

By Editor Type

  • Cytosine Base Editors
  • Adenine Base Editors
  • RNA Base Editors

By Delivery

  • Lipid Nanoparticle
  • AAV/Viral Vector
  • Ex Vivo Electroporation

By Setting

  • In Vivo
  • Ex Vivo

By Indication

  • Cardiovascular/Lipid Disorders
  • Hemoglobinopathies
  • Liver & Metabolic
  • Immunology & Oncology
  • Rare Genetic Disease

By End User

  • Biopharma
  • Academic & Research
  • CDMOs

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America
  • Geography Analysis
  • North America represents a major revenue-generating region in the global base editing market, supported primarily by the strength and maturity of the U.S. biopharmaceutical and biotechnology ecosystem. The region benefits from a highly developed research infrastructure that brings together leading universities, biotechnology companies, pharmaceutical organizations, clinical research institutions, specialized laboratories, and advanced manufacturing capabilities.
  • The United States plays a central role in regional market development because of its extensive clinical research capabilities and significant investment in genomic medicine. A large proportion of global clinical research activity in gene-editing technologies is conducted through U.S.-based institutions, supported by advanced healthcare infrastructure, specialized research centers, and access to substantial pools of scientific and financial expertise.
  • Canada further contributes to North America's position through its capabilities in biotechnology, genomic research, and drug-delivery technologies. Canadian universities, research institutions, and biotechnology companies have participated in the development of advanced delivery systems, including lipid nanoparticle (LNP) technologies that are increasingly important for the delivery of genetic medicines.

Leading Market Participants

  • Beam Therapeutics
  • Verve Therapeutics (Eli Lilly)
  • Prime Medicine
  • Korro Bio
  • Wave Life Sciences
  • ProQR Therapeutics
  • Chroma Medicine (nChroma Bio)
  • Base Therapeutics
  • YolTech Therapeutics
  • Broad Institute (licensor)
  • Pfizer
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Editas Medicine
  • BEAM-Apellis collaborations
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary

  • 1.1. Global Base Editing Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary Sources
    • 2.4.2. Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary Sources
    • 2.5.2. Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Base Editing Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Deaminase Enzyme / Guide-RNA & Reagent (Oligo) Suppliers
    • 3.1.2. Base-Editor (Cytosine, Adenine, RNA) Platform Developers
    • 3.1.3. LNP/AAV Delivery, Ex-Vivo Cell-Engineering & CDMO Manufacturing
    • 3.1.4. Clinical Development, Regulatory & Pharma Co-Development Partners
    • 3.1.5. End Users (Biopharma, Academic & Research, CDMOs)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Base Editing Industry
    • 3.2.2. Safer Single-Nucleotide Editing (No Double-Strand Breaks) & Shift to One-Time Curative In-Vivo Therapies (PCSK9/ANGPTL3)
    • 3.2.3. ABE Dominance (~50% Pathogenic Variants), LNP Hepatic Delivery, Platform-Based FDA Strategy, Ex-Vivo Allogeneic CAR-T Multiplexing & Off-Target Safety Infrastructure
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Editor Type

Chapter 4. Global Base Editing Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Base Editing Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Editor Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Cytosine Base Editors
        • 5.2.1.1.2. Adenine Base Editors
        • 5.2.1.1.3. RNA Base Editors
    • 5.2.2. By Delivery
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Lipid Nanoparticle
        • 5.2.2.1.2. AAV/Viral Vector
        • 5.2.2.1.3. Ex Vivo Electroporation
    • 5.2.3. By Setting
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. In Vivo
        • 5.2.3.1.2. Ex Vivo
    • 5.2.4. By Indication
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Cardiovascular/Lipid Disorders
        • 5.2.4.1.2. Hemoglobinopathies
        • 5.2.4.1.3. Liver & Metabolic
        • 5.2.4.1.4. Immunology & Oncology
        • 5.2.4.1.5. Rare Genetic Disease
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Biopharma
        • 5.2.5.1.2. Academic & Research
        • 5.2.5.1.3. CDMOs
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Editor Type
      • 6.2.1.2. By Delivery
      • 6.2.1.3. By Setting
      • 6.2.1.4. By Indication
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Editor Type
      • 7.2.1.2. By Delivery
      • 7.2.1.3. By Setting
      • 7.2.1.4. By Indication
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Editor Type
      • 8.2.1.2. By Delivery
      • 8.2.1.3. By Setting
      • 8.2.1.4. By Indication
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Editor Type
      • 9.2.1.2. By Delivery
      • 9.2.1.3. By Setting
      • 9.2.1.4. By Indication
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Editor Type
      • 10.2.1.2. By Delivery
      • 10.2.1.3. By Setting
      • 10.2.1.4. By Indication
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Beam Therapeutics
  • 11.2. Verve Therapeutics (Eli Lilly)
  • 11.3. Prime Medicine
  • 11.4. Korro Bio
  • 11.5. Wave Life Sciences
  • 11.6. ProQR Therapeutics
  • 11.7. Chroma Medicine (nChroma Bio)
  • 11.8. Base Therapeutics
  • 11.9. YolTech Therapeutics
  • 11.10. Broad Institute (licensor)
  • 11.11. Pfizer
  • 11.12. AstraZeneca
  • 11.13. Vertex Pharmaceuticals
  • 11.14. Editas Medicine
  • 11.15. BEAM-Apellis collaborations
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators